Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Major factor affecting intraocular pressure spikes after intravitreal ranibizumab injection: vitreous reflux and its amount
TCTR20180327001Completed
- Sponsor
- Enes Uyar
- Start
- Mar 2017
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of ranibizumab in retinal vascular disease, age-related macular degeneration (AMD) and diabetic macular edema (DME), sponsored by Enes Uyar. Primary endpoints: Intraocular pressure spikes after intravitreal ranibizumab injection and Vitreous reflux and its amount. Started Mar 2017; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinal vascular diseaseage-related macular degeneration (AMD)diabetic macular edema (DME)
Beyond the preview
Go deeper on TCTR20180327001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20180327001.